Drugs / DelNS1-nCoV-RBD LAIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04809389 | Mar 2021 → Sep 2022 | COVID-19 | The University of Hong Kong | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DelNS1-nCoV-RBD LAIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04809389 ↗ |
| Modality | Vaccine | “a novel nasal spray investigational vaccine” NCT04809389 ↗ |
| Route | Intranasal | “intranasal administration” NCT04809389 ↗ |